GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period

(Summary description)

GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period

(Summary description)

Information
The joint-stock company has been established, and its approval for listing on the National Equities Exchange and Quotations has been approved
GT0918 (Proxalutamide tablets) project has obtained clinical trials approval for breast cancer indications in China, and phase I/Ib clinical trials have been launched
GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period

Scan the QR code to read on your phone